Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 2Somatostatinoma 1Neuroblastoma 1Medulloblastoma 1

Interventions

Capecitabine 3Trastuzumab 2Temozolomide 2Sunitinib 2Octreotide 2Leucovorin 2Everolimus 2Bevacizumab 2vatalanib 1tipifarnib 1temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1cixutumumab 1batifiban 1aflibercept 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Salts 1Oxaliplatin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Somatostatinoma × pentetreotide × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡